News | February 05, 2022
Mangalam Drugs and Organics Q3FY22 PAT at Rs. 4.02 crore
Mangalam Drugs and Organics Limited has reported standalone financial results for the period ended December 31, 2021
Mangalam Drugs and Organics Limited has reported standalone financial results for the period ended December 31, 2021
Sanofi unveiled a new bold and unifying corporate brand that supports the modernization and transformation the company launched in December 2019
The recommendations have been sent to the Drugs Controller General of India (DCGI) for the final approval
Corbevax is administered through an intramuscular route with two doses scheduled 28 days apart and is stored between 2 degrees celsius to 8 degrees celsius
Lupin has reported consolidated financial results for the period ended December 31, 2021
New instrument helps maximize lab productivity and extends FTIR to large, heavy samples
The target demographic will be those between the ages of 30 and 65 years
Unlike “Fast PCR” platforms - which uses LAMP/Isothermal technology and not gold standard RT-PCR - CoviSwift has high accuracy and sensitivity and is suitable for airports and hospitals
The company has reported total income of Rs. 3715.8 crores during the quarter ended December 31, 2021
Restasis has been approved for use in the U.S. for nearly 20 years, but until today, there was no approved generic product of this drug
Subscribe To Our Newsletter & Stay Updated
